Skytrofa (Lonapegsomatropin-Tcgd) Patent Expiration, LOE Window & CMS Spending
Skytrofa (Lonapegsomatropin-Tcgd) by Ascendis Encocrinology Div A/S: Biologic BLA (Purple Book Regime), 0 AB generics, $118.4M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ascendis Encocrinology Div A/S |
| FDA Application & Pathway | B761177 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $118.4M |
| 2024 Medicare Part D Spend | $159K |
| 2024 Medicaid Spend | $118.2M |
| Reported Wholesale Price Change (CA SB 17) | 9 WAC filings (max 16.3% 2-yr change) |